Description of the medicine: Erythrophosphatide (Erytrophosphatidum)
A drug derived from human blood red blood cells. Contains glycerophospholipids: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylmyelin.
Yellowish opalescent emulsion; pH 5, 5 - 6, 8.
Glycerophospholipids play an important role in the vital processes of the body; being components of biological membranes, they affect their permeability, participate in the transmission of nerve impulses, in energy processes.
As a medicine, erythrophosphatide is used as a hemostatic, hemostimulating and desensitizing agent.
It is used in adults with hemorrhagic diathesis associated with impaired thrombosis, Werlhof’s disease, hypo- and aplastic anemia, leukemia, etc., with blood coagulation disorders due to insufficiency of factors VIII, IX, V, VII, etc. Corresponding hemocoagulating can be used simultaneously. facilities.
As an antianemic agent, erythrophosphatide is prescribed for the complex treatment of chronic posthemorrhagic, iron deficiency, hypoplastic and other anemias.
As a desensitizing agent, the drug is used for diseases accompanied by auto- and isohemosensitization phenomena.
Apply erythrophosphatide intramuscularly.
To enhance blood coagulation, 150-300 mg are administered (for adults) in 1 to 2 days. The maximum effect is observed 2 to 3 hours after intramuscular administration. If necessary, injections are performed 2 to 3 times a day for 2 to 3 days or more. The daily dose is 750 mg.
For anemia, erythrophosphatide is administered at 150 mg once every 4 to 5 days, for a total of 10 to 15 injections. In case of anemia with a pronounced violation of bone marrow hematopoiesis, the course dose of the drug can be increased to 30 to 50 injections.
In the case of severe acute or chronic hypoxia due to deep anemia, when the patient needs a blood transfusion, and blood transfusions cause sensitization, erythrophosphamide is administered intramuscularly 1 to 2 hours before the blood transfusion for desensitization.
The drug is contraindicated in case of increased blood coagulation.
Release form: in ampoules containing 5 ml of the drug (emulsion), in a package of 10 ampoules.
Storage: at a temperature of + 4 to + 8'C in a dark place.